These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 2030734)

  • 1. Market heats up for US biotech companies.
    Gershon D
    Nature; 1991 May; 351(6322):86. PubMed ID: 2030734
    [No Abstract]   [Full Text] [Related]  

  • 2. Stock market crash threatens start-up biotech companies.
    Lehrman S
    Nature; 1998 Sep; 395(6698):104. PubMed ID: 9744257
    [No Abstract]   [Full Text] [Related]  

  • 3. Biotech's perfect storm.
    Karberg S
    Cell; 2009 Aug; 138(3):413-5. PubMed ID: 19665960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Australia's bio-regulatory framework: leading the way for stem cell research.
    Hill H
    J Biolaw Bus; 2004; 7(2):61-4. PubMed ID: 15460561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patent holdings of US biotherapeutic companies in major markets.
    Sebastian TE; Yerram CB; Saberwal G
    Drug Discov Today; 2009 May; 14(9-10):442-5. PubMed ID: 19429502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health reforms 'could hit biotech companies'.
    Gershon D
    Nature; 1994 Mar; 368(6468):180. PubMed ID: 8145812
    [No Abstract]   [Full Text] [Related]  

  • 7. Market entry and exit by biotech and device companies funded by venture capital.
    Burns LR; Housman MG; Robinson CA
    Health Aff (Millwood); 2009; 28(1):w76-86. PubMed ID: 19049998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Damon to form separate lab and biotech companies.
    Wagner M
    Mod Healthc; 1988 Apr; 18(18):5. PubMed ID: 10287267
    [No Abstract]   [Full Text] [Related]  

  • 9. Public biotechnology 2005--the numbers.
    Lähteenmäki R; Lawrence S
    Nat Biotechnol; 2006 Jun; 24(6):625-34. PubMed ID: 16763588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. US biotech firms line up for tax credits.
    Ledford H
    Nature; 2010 Jun; 465(7300):854-5. PubMed ID: 20559355
    [No Abstract]   [Full Text] [Related]  

  • 11. Biotech bailout? A rescue of some sort will be needed to save a large subset of the US biotechnology industry.
    Nat Immunol; 2009 Jul; 10(7):667. PubMed ID: 19536186
    [No Abstract]   [Full Text] [Related]  

  • 12. Market woes drag down biotech shares.
    Morrison C
    Nat Biotechnol; 2001 Nov; 19(11):995-6. PubMed ID: 11689828
    [No Abstract]   [Full Text] [Related]  

  • 13. Minicrash tests biotechnology investors and companies as market fluctuates.
    Dorey E
    Nat Biotechnol; 1997 Dec; 15(13):1333. PubMed ID: 9415878
    [No Abstract]   [Full Text] [Related]  

  • 14. The further evolution of biotech.
    Nagle T; Berg C; Nassr R; Pang K
    Nat Rev Drug Discov; 2003 Jan; 2(1):75-9. PubMed ID: 12509762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biotech jostles with pharma for slice of HIV market.
    Katsnelson A
    Nat Biotechnol; 2006 Jan; 24(1):3-4. PubMed ID: 16404375
    [No Abstract]   [Full Text] [Related]  

  • 16. The biotech drug market.
    Lawrence S
    Nat Biotechnol; 2004 Dec; 22(12):1496. PubMed ID: 15583645
    [No Abstract]   [Full Text] [Related]  

  • 17. A good year for US biotech, but caution is still advised.
    Lehrman S
    Nature; 1996 Jan; 379(6562):194. PubMed ID: 8538776
    [No Abstract]   [Full Text] [Related]  

  • 18. Building a better biotech company.
    Turner L
    Nat Biotechnol; 1999 Feb; 17 Suppl():BE5-6. PubMed ID: 10052312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. US government previews biotech survey.
    Goho A
    Nat Biotechnol; 2003 Aug; 21(8):837-8. PubMed ID: 12894185
    [No Abstract]   [Full Text] [Related]  

  • 20. Tough times set to continue for US biotech start-ups.
    Lehrman S
    Nature; 1999 Jan; 397(6716):191. PubMed ID: 9930684
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.